Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria.
Rheumatology (Oxford). 2023 Oct 23;62(SI3):SI282-SI285. doi: 10.1093/rheumatology/kead436.
Given the high prevalence and the enormous impact on key outcomes, comorbidities are important to consider, especially in patients with RA. Comorbidity indices are tools to quantify the impact of the overall burden of coexisting diseases on a specific outcome of interest. Until now, no gold standard exists on how to measure comorbidities. A large variety of indices have been developed using different settings and therefore leading to conceptual differences. Choosing the right tool clearly depends on the intention (clinical or research purpose) and the specific research question. The current article will address the purpose and challenge of measuring comorbidities in RA patients.
鉴于其高患病率和对关键结局的巨大影响,共病是需要考虑的重要因素,尤其是在 RA 患者中。共病指数是一种用于量化共存疾病整体负担对特定关注结局影响的工具。到目前为止,尚无衡量共病的金标准。已经使用不同的设置开发了多种指数,因此导致了概念上的差异。选择合适的工具显然取决于目的(临床或研究目的)和具体的研究问题。本文将讨论在 RA 患者中测量共病的目的和挑战。